You are here: Home » Reuters » News
Business Standard

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

Reuters  |  FRANKFURT 

(Reuters) - KGaA and Pfizer's drug could not be shown to improve survival in patients that had previously undergone unsuccessful chemotherapy, said.

The results revealed on Thursday mark another setback for a drug that is a late starter in the rapidly evolving field of

shares turned negative following the news, trading 1.1 percent lower.

(Reporting by Ludwig Burger; Editing by Edward Taylor)

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, February 15 2018. 20:00 IST
RECOMMENDED FOR YOU